Search research articles
Contact Us
Filters
Showing results (81-90 of 121) with videos related to
Page
of 13
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1995
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study
M J Ratain, G Rosner, S L Allen, et al.
American Journal of Hematology
|
January 12, 1999
Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen
R L Bayer, S M Lichtman, S L Allen, et al.
Blood
|
June 1, 1991
Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis
A Foti, H G Ahuja, S L Allen, et al.
The American Journal of Medicine
|
March 1, 1987
Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors
M H Kaplan, M Susin, S G Pahwa, et al.
Age and Ageing
|
May 1, 1992
Use of cisplatin for elderly patients
S M Lichtman, M Buchholtz, J Marino, et al.
Leukemia & Lymphoma
|
July 27, 2016
Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule
S M Lichtman, A Mittelman, D R Budman, et al.
Leukemia
|
November 1, 1991
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study
W Kreis, D R Budman, K Chan, et al.
Investigational New Drugs
|
January 1, 1996
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
S L Allen, L P Schacter, S M Lichtman, et al.
The Journal of Experimental Medicine
|
April 1, 1995
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells
S Hashimoto, M Dono, M Wakai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1994
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors
D R Budman, L N Igwemezie, S Kaul, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 121) with videos related to
Sort By:
Page
of 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1995
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study
M J Ratain, G Rosner, S L Allen, et al.
American Journal of Hematology
|
January 12, 1999
Acquired factor VIII inhibitors--successful treatment with an oral outpatient regimen
R L Bayer, S M Lichtman, S L Allen, et al.
Blood
|
June 1, 1991
Correlation between molecular and clinical events in the evolution of chronic myelocytic leukemia to blast crisis
A Foti, H G Ahuja, S L Allen, et al.
The American Journal of Medicine
|
March 1, 1987
Neoplastic complications of HTLV-III infection. Lymphomas and solid tumors
M H Kaplan, M Susin, S G Pahwa, et al.
Age and Ageing
|
May 1, 1992
Use of cisplatin for elderly patients
S M Lichtman, M Buchholtz, J Marino, et al.
Leukemia & Lymphoma
|
July 27, 2016
Phase II Trial of Fludarabine Phosphate in Multiple Myeloma Using a Loading Dose and Continuous Infusion Schedule
S M Lichtman, A Mittelman, D R Budman, et al.
Leukemia
|
November 1, 1991
Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study
W Kreis, D R Budman, K Chan, et al.
Investigational New Drugs
|
January 1, 1996
Phase II study of elsamitrucin (BMY-28090) for the treatment of patients with refractory/relapsed non-Hodgkin's lymphoma
S L Allen, L P Schacter, S M Lichtman, et al.
The Journal of Experimental Medicine
|
April 1, 1995
Somatic diversification and selection of immunoglobulin heavy and light chain variable region genes in IgG+ CD5+ chronic lymphocytic leukemia B cells
S Hashimoto, M Dono, M Wakai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1994
Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors
D R Budman, L N Igwemezie, S Kaul, et al.
Page
of 13